
    
      In this study, participants will be children aged 1-5 years who have recurrent wheezing and
      will be allocated to one of two treatment groups, either current clinical care or airway
      microbiota and blood eosinophils phenotype based management for 3 months.They will be
      followed up for one year after the intervention. The primary outcome is the frequency of
      unscheduled healthcare visit for wheezing, the secondary outcome parameters are events of
      severe wheezing requiring oral or intravenous steroids, events of emergency department visit
      and hospital admissions, the changes of Test for Respiratory and Asthma Control in Kids
      (TRACK) score and Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) score.
    
  